Cetera Investment Advisers
STLN

Cetera Investment Advisers’s Starling Oncology STLN Stock Holding History

Cetera Investment Advisers’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$486K Sell
89,415
-38,780
-30% -$163K ﹤0.01% 3725
2026
Q1 		$394K Buy
128,195
+103,908
+428% +$319K ﹤0.01% 3734
2025
Q4 		$86.5K Sell
24,287
-20,958
-46% -$77.7K ﹤0.01% 4437
2025
Q3 		$158K Buy
45,245
+27,700
+158% +$94.9K ﹤0.01% 4220
2025
Q2 		$36K Buy
17,545
+4,545
+35% +$11.4K ﹤0.01% 3994
2025
Q1 		$14.8K Buy
+13,000
New +$10.1K ﹤0.01% 3928

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Cetera Investment Advisers's STLN Position: Q2 2026 in Review

Cetera Investment Advisers reduced its Starling Oncology (STLN) stake by 30% in Q2 2026, selling an estimated $163K and leaving 89,415 shares worth $486K. The position accounts for ﹤0.01% of the portfolio, ranked #3725.

Cetera Investment Advisers first reported a position in STLN in Q1 2025 and has held it in 6 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Cetera Investment Advisers held 89,415 shares of Starling Oncology worth $486K as of Q2 2026.
  • Cetera Investment Advisers sold 38,780 Starling Oncology shares in Q2 2026, an estimated $163K.
  • Starling Oncology made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #3725 holding.
  • Cetera Investment Advisers first reported a position in Starling Oncology in Q1 2025 and has held it in 6 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.